A Study on the Mechanism of Cinobufagin in the Treatment of Paw Cancer Pain by Modulating Local β-Endorphin Expression In Vivo

Figure 4

The representative photomicrographs of the tumor and adjacent tissues β-END immunohistochemistry (400x) and effect of Cinobufagin on the tumor and adjacent tissue β-END protein expressions in the cancer pain mice. (a) Control group; (b) model group; (c) cinobufagin group (Cinobufagin, 10 mL/kg/day, i.p.); (d) cinobufagin + NAL-M group (Cinobufagin, 10 mL/kg/day, NAL-M, 20 mg/kg/day i.p.); (e) morphine group (morphine, 8 mg/kg/day, i.p.). (f) Effect of Cinobufagin on the tumor and adjacent tissue β-END protein expression. Label with red arrowheads represents β-END positive expression. Data are shown as the mean ± SD (𝑛=6). ^#𝑃<0.05, ^##𝑃<0.01 compared to control group; *𝑃<0.05, **𝑃<0.01 compared to model group.

(a)  

(b)

(c)

(d)

(e)

(f)